Otsuka seems to think it’s onto something by using digital tech to aid treatment of mental health disorders: in November 2017 its Abilify MyCite, a combination of the company’s antipsychoti
Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d